Last update April 12, 2025

フシジン酸

Compatible

Safe product and/or breastfeeding is the best option.

Fusidic acid and its salts such as sodium fusidate are antibacterials mainly used in the treatment of staphylococcal infections. Oral, intravenous and topical dermatological and ophthalmological administration.

Its pharmacokinetic data (moderately high molecular weight and high percentage of protein binding) explain the minimal passage into milk observed. (Leo 2012 & 2010, Lauen 1969 cited in LactMed)

Intestinal absorption is hindered by simultaneous feed intake, which minimises passage into the infant's plasma.

Authorised systemic use in neonates and infants It competes with bilirubin in binding to albumin, so in the first month of life and more so in premature infants, it is necessary to monitor the appearance of neonatal jaundice.

TOPICAL DERMATOLOGICAL USE:

Low absorption (0.54%) through the skin makes it unlikely that a significant amount will pass into breast milk. (Leo 2017 & 2012)

Not effective and may even be detrimental in the local treatment of cracks or nipple infections (Livingstone 1999) and mastitis. (Crepinsek 2010)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

フシジン酸 is Fusidic Acid in Japanese.

Is written in other languages:

フシジン酸 is also known as

Tradenames

Main tradenames from several countries containing フシジン酸 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 70 - 91 (Dermat: 0.5) %
Molecular weight 526 daltons
Protein Binding 97 - 99 %
pKa 4.46 -
Tmax 4 hours
6 - 10 hours
Theoretical Dose 0.0008 - 0.129 mg/Kg/d
Relative Dose 0.002 - 0.26 %

References

  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/ 2006 - Consulted on April 16, 2024 Full text (link to original source)
  2. Leo Ph. Fusidic acid. Drug Summary. 2017 Full text (in our servers)
  3. Leo Pharma. Ácido fusídico, crema. Ficha técnica. 2012 Full text (in our servers)
  4. Leo Pharma. Ácido fusídico. Ficha técnica. 2010 Full text (in our servers)
  5. Crepinsek MA, Crowe L, Michener K, Smart NA. Interventions for preventing mastitis after childbirth. Cochrane Database Syst Rev. 2010 Abstract
  6. Livingstone V, Stringer LJ. The treatment of Staphyloccocus aureus infected sore nipples: a randomized comparative study. J Hum Lact. 1999 Abstract
  7. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents. 1999 Abstract
  8. Lauen O. [Acute puerperal mastitis treated with Fucidin]. Tidsskr Nor Laegeforen. 1969 Jun 1;89(11):816-9. Norwegian. No abstract available. Abstract

Total visits

2,901

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM